Patient-specific dosimetric verification methods for IMRT treatments are variable, time-consuming and frequently qualitative, preventing evidencebased reduction in the amount of verification performed. This paper addresses some of these issues by applying a quantitative analysis parameter to the dosimetric verification procedure. Film measurements in different planes were acquired for a series of ten IMRT prostate patients, analysed using the quantitative parameter, and compared to determine the most suitable verification plane. Film and ion chamber verification results for 61 patients were analysed to determine long-term accuracy, reproducibility and stability of the planning and delivery system. The reproducibility of the measurement and analysis system was also studied. The results show that verification results are strongly dependent on the plane chosen, with the coronal plane particularly insensitive to delivery error. Unexpectedly, no correlation could be found between the levels of error in different verification planes. Longer term verification results showed consistent patterns which suggest that the amount of patient-specific verification can be safely reduced, provided proper caution is exercised: an evidence-based model for such reduction is proposed. It is concluded that dose/distance to agreement (e.g., 3%/3 mm) should be used as a criterion of acceptability. Quantitative parameters calculated for a given criterion of acceptability should be adopted in conjunction with displays that show where discrepancies occur. Planning and delivery systems which cannot meet the required standards of accuracy, reproducibility and stability to reduce verification will not be accepted by the radiotherapy community.
Introduction
Intensity modulated radiotherapy (IMRT) is increasingly coming into clinical use. However, the biggest barrier to its more widespread use is the extremely time-consuming dosimetric verification required on a patient-by-patient basis, especially given that linear accelerator (linac) availability for verification measurements is normally after normal hours. It is therefore imperative that verification methods are made more efficient and that the amount of verification performed is reduced to a safe minimum level as soon as possible. A high level of patientspecific verification at the start of IMRT implementation is recognized to be necessary in the light of the increased planning and delivery complexities of IMRT. Reduction of verification should only be considered when sufficient numbers of patients for a particular clinical site have been comprehensively verified and the IMRT system shown to be accurate, reproducible and stable. However, as recently pointed out by Niemierko (2004) , there is currently little in the literature to suggest what constitutes an acceptable point for reduction in verification. Indeed, there is still a debate as to whether patient-specific verification can ever be dispensed with (Dube 2003 , Ramsey 2003 .
One of the problems with IMRT verification is the qualitative nature of the checks often performed. A typical procedure is to make film measurements in a phantom of either the individual beam fluences or the combined dose distributions, digitize the films, convert to an isodose display and compare visually with an isodose display of the in-phantom dose calculated by the planning system (James et al 2004) . Because this is a purely qualitative procedure, it is very difficult to determine what is an acceptable match; this depending on the subjective judgement of the user. An improved technique is to import the planning dose grids into comparison software and use standard tools such as difference maps, profile overlays and isodose overlays to examine the differences between dose distributions. Although an improvement on a visual comparison, it is still difficult to set quantitative acceptance tolerances using these kinds of tools. Attempts have been made such as creating histograms of the dose differences between the two dose distributions, and setting a tolerance such that x% of pixels must have a dose difference of less than ±y%. However, this type of tolerance suffers from the setback that it is entirely dose based and takes no account of the large dosimetric errors generated when matching steep dose gradients. Tolerances should therefore be based on quantitative parameters which take into account both dosimetric and positional errors.
This problem has previously been addressed by the work of Van Dyk et al (1993) who developed the concept of using a distance to agreement (DTA) criterion in areas of high dose gradient (defined as >30%/cm) and a dosimetric criterion in low dose gradients for the purpose of testing planning system accuracy. They suggested criteria of 3% dosimetric agreement and 4 mm DTA as achievable for the planning systems then in use (this type of tolerance will henceforth be represented as 3%/4 mm) although urging improvements in dose calculations towards the 2%/2 mm criterion recommended by the ICRU (1987) . For conventional beams which essentially consist only of a low dose gradient plateau and high dose gradient edges, this approach is suitable. For IMRT, in which the dose gradients vary considerably and in which beams may have large areas of medium dose gradient, for which neither criterion obviously applies, this type of tolerance is difficult to apply. This problem was addressed by Low et al (1998) who developed the gamma concept which simultaneously tests each pixel with a dosimetric and a DTA criterion. This analysis results in a single number (the gamma value) for each pixel which represents the goodness of match between the two dose distributions. This concept has been extended further by Depuydt et al (2002) , who show that by setting a tolerance on the gamma value (which is related directly to the specified x%/y mm criterion), a pass/fail gamma image can be generated which shows the exact areas of the dose distribution which fail the tolerance.
Even using these approaches, there is still no consensus on what are acceptable tolerances for IMRT, either for film or ion chamber measurements. Tolerances have been suggested for IMRT by Wang et al (1996) of 3%/3 mm based on a report by Masterson et al (1991) . Ezzell et al (2003) , in an AAPM report, state: "For more complex irradiations typical of patient treatments, there is a developing consensus that ion chamber measurements in high dose, low gradient regions should agree with the plan to within 3% to 4% . . . with the understanding that small field and localized gradients may cause additional uncertainties in some cases." Chui and LoSasso (2000) state: "In general, agreement between calculated and measured doses within 2% or 2 mm can be achieved." Dong et al (2003) found measured/calculated differences of 0.3% ± 1.8% (1 SD) for ion chamber checks of 420 6 MV step and shoot MLC patients, with a range of −4.5% to +9.5%. Xing et al (1999) report 90% and 60% measured isodose curves lying within 3 mm and 4 mm, respectively, of the calculated isodoses. Pignoli et al (2000) measured mean (±1 SD) displacements from the calculated isodoses of 1.0 ± 0.6 mm, 1.2 ± 0.7 mm and 1.5 ± 1.1 mm for the 80%, 50% and 20% isodose lines, respectively, in the axial plane. However, no formal recommendations have yet been made as to suitable tolerances. Even where tolerances have been suggested, it is not clear whether they should be applied to the dose distributions for individual beams (often referred to as fluence maps which terminology will be used throughout this paper, although technically fluence is defined in-air) or to the combined dose distributions. It is additionally unclear as to whether the whole distribution has to meet the tolerance in order to be acceptable, or whether a high proportion should meet the tolerance. Finally, should the same tolerances apply to the high dose regions as to the low dose regions outside the treated volume? At these doses, film dosimetry is known to be less accurate and there may be less concern about dose agreement in these regions. However, Schwarz et al (2003) have recently highlighted problems that may arise from dose discrepancies outside the treated volume. A compounding problem is the accuracy of the verification methods being used, which should be taken into account in setting tolerances.
This paper seeks to address some of these issues by applying a quantitative analysis parameter based on the gamma concept to the verification procedure. The analysis has been used to quantify errors for a prostate IMRT technique and to compare the results obtained for the different dose planes commonly used for IMRT verification. The results are then used to address some of the questions raised above and to develop some practical recommendations for verification. The limitations of the results, being based on a small volume treatment site and analysis volume, are also discussed.
Methods

IMRT verification technique
The verification technique described here was developed for an 8 MV, 5-field hypofractionated prostate IMRT trial which includes a boost dose to the prostate (Amer et al 2003 , Mott et al 2004 . Sixty-one patients have been treated in this trial, 30 with a boost dose of 57 Gy in 19 fractions, 31 with a boost dose of 60 Gy in 20 fractions. All 61 patients have been subject to the following patient-specific verification. First, a 0.125 cc ion chamber measurement in a semi-anatomically shaped water/water equivalent phantom (figure 1). Initially, dose was measured at isocentre; a review of the verification technique after the first 17 patients led to the measurement point being changed to 0.5 cm superior of isocentre to avoid interleaf effects (for this model of accelerator). This is an absolute dose check and replaces the conventional monitor unit (mu) check. The dose for each beam was measured separately. Secondly, the combined dose distribution was measured using film in a solid semi-anatomic Perspex phantom in three transverse planes ( figure 2(a) ). Again, the chosen planes were changed from the isocentric plane and ±2.5 cm (before the verification review) to planes at −1.5 cm, 0.5 cm and 2.5 cm (positive indicating towards the gantry). For the first ten patients treated, additional verification checks were applied which included the following: the fluence map for each beam was delivered to a film at a depth of 19 mm (d max ) in a flat solid water-equivalent phantom with the linac gantry angle set at 0
• . Also, the combined dose distribution was measured in the Perspex semi-anatomical phantom in the coronal plane through the isocentre ( figure 2(b) ). Kodak EDR2 film (Zhu et al 2002 , Olch 2002 , Dogan et al 2002 was used in order to avoid optical density saturation and films were digitized using a Vidar VX12 scanner (Vidar Systems Corporation) and Poseidon software version 4.1A (MDS Nordion).
Film measurement analysis
A software package has been developed in the IDL (Interactive Data Language, Research Systems, Inc.) programming language to import, register, normalize and compare the digitized film images and dose grids from the planning system (in this case Nucletron Plato). The software may be used for both fluence maps and combined dose distributions. Optical density to dose conversion is possible but in this analysis was used only to convert the films from relative optical density to relative dose; absolute dosimetry was not attempted. The film isocentre is identified from pinpricks and registered with the planning data. Further small shifts are allowed to account for the effects of small set-up uncertainties. An automated root-mean-square comparison of the two images is provided to achieve the final registration. No attempt is made to rotate the images during registration. The films are normalized to a small area at the isocentre, the dose at which has been previously calculated by the planning system; this is normally an appropriate high dose, low dose gradient area of dose but the normalization and/or normalization point may be adjusted if this point coincides with a low dose or steep dose gradient. Basic tools provided include overlaid isodose images and interactive overlaid x and y profiles. Profiles, isodoses and histograms of the dose difference image can also be displayed.
The gamma concept has been implemented using the technique of Depuydt et al (2002) . A dose/distance criterion is specified and a pass/fail image generated which shows which parts of the image have failed to meet the criterion. A useful display consists of the overlaid isodoses superimposed onto the gamma image-this has been found to show at a glance whether the measurement is satisfactory (figure 3). Overlaid x and y profiles interactively drawn through the cursor position in this image provide an immediate method to investigate the cause of the match failure. The quantitative analysis parameter used is defined as the number of failing pixels in the gamma image within a user-specified planning isodose. For instance, in figures 3(a) and (b), 0.3% and 1.35% of pixels, respectively, fail to meet the 3%/3 mm gamma criterion within the 80% isodose line. This quantitative analysis parameter has been applied to the three combined transverse dose distributions for all 61 patients treated. For the first ten patients, the analysis has also been applied to the combined coronal dose distributions and to the fluence maps for each individual beam.
Reproducibility of measurements and analysis
A study was carried out to determine the reproducibility of the ion chamber measurements and combined dose distribution film measurements as a baseline against which to evaluate the planning system versus measurement results. A complex combined dose distribution representing a 'worst-case scenario' for IMRT (a very large C-shaped target volume surrounding an organ at risk) was used for all the measurements. All measurements were made using the same prescription, phantom and linac following the same procedure each time. Ion chamber measurements at isocentre were measured five times over eight months by the same operator. Transverse film measurements of the isocentric plane were measured independently four times by three different operators (operator 1 performing the measurement twice) in the same phantom on the same linac on the same afternoon. The same measurement was also performed by one of the operators four months previous to this experiment. All the films were analysed by one of the operators using the film analysis software described above using one of the films as the reference dose distribution in order to determine the fundamental repeatability of such film measurements.
Results
Monitor unit checks
The results of the ion chamber measurements for all patients are shown in figures 4 and 5. Figure 4 shows the deviation of measured dose from calculated dose for each individual beam (as well as the combined result) for the first (57 Gy) arm of the trial. A tolerance of 3% for each individual beam was set and is marked on the graph. Deviations outside this tolerance were investigated and were all found to be due to tongue and groove under-doses, or were measurements in high dose gradients. A similar pattern in individual beams was seen for the 60 Gy arm of the trial. Figure 5 shows the combined dose from all five beams for all 61 patients. The 2% tolerance applied to the combined doses is marked on the graph. Patients 50-58 in the 60 Gy arm of the trial were affected by a systematic drop in measured dose of 0.8%. On investigation, this was found to be due to a beam symmetry instability in the gun-target (GT) plane, which gave QC results within normal QC tolerances but which affected the low dose segments used for IMRT. On correction of this problem, the patient doses were re-measured and gave results consistent with previous measurements, as shown in the graph. Of the four cases where the overall dose fell outside the 2% tolerance, three can be attributed to the GT asymmetry problem and the fourth (patient 11 in the 57 Gy arm) was caused by large tongue and groove under-doses in two of the five beams (see figure 4) . Overall agreement between measured and calculated doses was −0.5 ± 0.7% (1 SD) for the 57 Gy arm of the trial and −1.0 ± 0.5% for the 60 Gy arm (corrected for the GT asymmetry problem).
Film dosimetry results
The quantitative parameter for the fluence map films for the first ten patients is shown in figure 6 ; the mean value is 3.6% and 0.6% for the 3%/3 mm and 4%/4 mm parameters, respectively, calculating the percentage of failing pixels inside the 80% isodose line. In choosing a tolerance for fluence maps it seems more sensible to use the 4%/4 mm criterion since these errors will be averaged out over multiple beams: a suggested 2% tolerance is marked in figure 6 (b). Figure 7 shows the results of the quantitative analysis for the three transaxial films for all 61 patients, using a 3%/3 mm gamma criterion and the 80% isodose line. The results of the same analysis for the isocentric coronal slice for the first ten patients are also displayed in figure 7 (a). The mean value for each plane is 0.8%, 1.6%, 0.6% for the 0.0/0.5 cm, +2.5 cm, −2.5/−1.5 cm transaxial planes, respectively, and 0.2% for the coronal plane. A 2% tolerance, which was used as a trigger for further investigation, is marked on the graph. Clearly, there are a number of patients for whom at least one film failed this initial tolerance. If there was a suspicion of set-up error the films were repeated. Otherwise, in these cases our procedure was to check the normalization and then to re-calculate at the 4%/4 mm level. If the film still fell outside the 2% tolerance, or if more than one transaxial slice required re-computing at the 4%/4 mm level (e.g., patient 5 in the 57 Gy arm), the results were shown to a clinician, who decided whether the delivery was acceptable on clinical grounds. In practice, in only two cases did the 4%/4 mm film fall outside the 2% tolerance. The first was the +2.5 cm film for patient 46 (in the 60 Gy arm), this proved to be a patient with a very short PTV; hence the slice was in the very high superior-inferior dose gradient at the end of the field. The second was patient 44 (in the 60 Gy arm), for whom the errors could be explained by a 2 mm set-up error in the phantom position; previously such a measurement would have been repeated, but by this time we were confident in the technique and proceeded to treatment on the basis of the ion chamber check being satisfactory. A number of observations may be drawn from the results shown in figures 6 and 7. Firstly, the magnitude of the 3%/3 mm quantitative parameter differs substantially depending upon the plane in which the film is positioned. Whereas this would be expected when comparing fluence maps with combined distributions, since any errors are likely to be averaged out over multiple beams, it is surprising that there is such a noticeable difference between the coronal and transverse results. For the transverse slices, the −2.5 cm inferior slice that was used initially gave much smaller values than the other two slices. This was found to be due to this slice being very near to the end of the PTV, in a region of almost uniform dose, hence there is little chance of inconsistency in this portion of the treated volume. The −1.5 cm transaxial slice used subsequently gives similar results to the 0.0/+0.5 cm slice. The +2.5 cm slice regularly gave larger errors than either of the other two transaxial slices; this is due to its normally being positioned in the boost region of the PTV, in a region where there is greatest degree of dosimetric variation in the combined dose distribution. Hence this slice is more sensitive to any dose discrepancies. Interestingly, the coronal slice gives much lower results, all <1% with an average of 0.2%.
Comparisons of different dose planes
Intuitively, it must be the case that where there are large areas of non-agreement between delivered and planned dose in the delivered fluence maps, this must give rise to errors in the combined three-dimensional (3D) dose distribution, although reduced in severity by the averaging effect of multiple beams. This being the case, one would expect to see a relationship between the measured error in the fluence maps and that measured in the combined dose distributions. This relationship was investigated and the results are shown in figures 8 and 9. Whilst in both cases there are patients for whom a large error in the fluence maps translates to a similarly large error in the combined distribution, there are also a number for whom there appears to be no such relation. The gamma criterion was varied and the results were re-mapped to determine whether specifying too high a criterion might be masking small error effects, but no substantial difference was seen in the results, therefore they are not shown here.
There are several possible reasons why no obvious relationship is seen between the fluence maps and the combined dose distributions. One is that the errors we are looking at are relatively small in plans which are being delivered reasonably accurately; the noise in the data created by small variations in normalization and registration may be masking the relationship. (This is particularly the case for the isocentric coronal planes, which appeared to be particularly non-sensitive to error detection.) If a larger data series were used, with larger errors deliberately introduced, the relationship would be more readily observed. A second possibility is that of the known variation in film sensitivity in different orientations and under different scatter conditions (Williamson et al 1981 , Martens et al 2002 , which will introduce different dose uncertainties in the different planes. Furthermore, there are specific problems for the transaxial slices: they were found to be much more prone to set-up error than the coronals (none of which had to be repeated), hence small rotations or air pockets may give rise to apparent localized dose deviations. Additionally, they sample a single line through each fluence map corresponding to one leaf pair (or possibly two, dependent on beam divergence and slice position); hence regions of error in the fluence maps will either be missed or amplified by projection along ray-lines through the transaxial plane.
Reproducibility of measurements and analysis
One standard deviation of ion chamber isocentre measurements was found to be 0.7%, with a range of 1.6%. On two occasions measurements were made within 24 h; the maximum difference found on the same day was 0.4%. The results of the film measurement reproducibility study are shown in table 1. This shows that for the analysis process used in this hospital there are significant differences between repeated films at the 1%/1 mm level, small differences at the 2%/2 mm level and almost no difference at the 3%/3 mm level. This suggests that 2%/2 mm is the minimum criterion of acceptability that could ever be used given these limits of accuracy for the verification system but that 3%/3 mm is a more realistic criterion the results for which should not be significantly affected by the system reproducibility.
Discussion
IMRT is now used widely and a great deal of time and effort is being taken up in developing methods for (and carrying out) patient-specific measurements. However, there has been little comparison or analysis of these methods to determine which is the most suitable for the purpose. In this discussion, the results presented in this paper will be used to address these issues.
Tolerances or criteria?
The first issue which requires clarification is precisely how to measure the accuracy of an IMRT delivery. In this paper, we have used the vocabulary of Van Dyk et al (1993) who suggested 'criteria of acceptability' of, for instance, 3%/4 mm. Whilst a simple tolerance can be applied to dose measurements at a single point (such as those shown in figures 4 and 5), when 2D or 3D dose distributions are compared they tend to match in certain regions and not in others. Figure 7 shows that if the 3%/3 mm criterion we have used were used as a strict tolerance, the results for many of the patients would fail the tolerance. If on the other hand, a looser tolerance of say 5%/5 mm were used, plans could be accepted which contained systematic dose differences. It seems better to adopt our method of applying a stricter criterion of acceptability and then quantifying the deviation from that criterion. A suitable tolerance, determined by experience, can then be applied to the quantitative parameter used.
This raises the issue of the definition of a tolerance. One definition would be a value outside of which a plan cannot be used clinically and within which it is safe. However, the tolerances we suggest in this paper are rather action levels at which the plan must be investigated further. For instance, if an area of disagreement is 4% high within the boost volume that may well be judged clinically acceptable. If the area is a 4 mm shift of the back edge of the PTV into the rectum, that is likely unacceptable. Displays such as those shown in figure 3 illustrating the location of discrepancies are therefore extremely valuable.
Quantitative parameters
A number of different quantitative parameters for describing the agreement between dose distributions have been described in the literature. The simplest measure is the mean and standard deviation of the dose difference. Pignoli et al (2000) used the mean and standard deviation of displacements from calculated isodose lines. Ma et al (1997 Ma et al ( , 2003 have used both linear and χ 2 global correlation coefficients to quantify dose differences. These methods all suffer from looking at either the dose or the DTA only. Harms et al (1998) therefore describe a tool which displays a 'composite evaluation' which shows areas which have failed both dose difference and DTA criteria. The method of Low et al (1998) provides a gamma value based on dose and DTA for each pixel; this can then be used to provide a mean and standard deviation gamma value based on both dose and DTA parameters and therefore provides a better single value parameter. However, any method that provides a single average value for a whole dose area runs the risk of disguising small areas of large disagreement which may be clinically significant. This is particularly a problem for IMRT deliveries which are much more likely to generate such localized hot or cold spots compared with other techniques. Therefore, it seems wiser to use techniques which highlight the areas of error such as those described by Harms et al (1998) , Depuydt et al (2002) and Childress and Rosen (2003) . While quantitative parameters may be calculated for these, such as the method we have described, it is important to note that it is not sufficient to always rely on a single parameter being inside a tolerance. The locations of errors should be checked, as described in the last section, and tools must be provided to examine areas of error in more detail. The tools we have found to be particularly useful are as follows. First, interactive profile overlays which allow excellent visualization of dose discrepancies. Second, re-calculation of the gamma image using a slightly higher criterion of acceptability (normally 4%/4 mm); if the errors are not present in the 4%/4 mm image this demonstrates that the localized error is not unacceptably large. Other tools such as dose difference isodoses and maps have not been found useful, although the dose difference histogram is an excellent method to check that the normalization is correct.
The biggest problem with all the quantitative parameters described is their dependence on area (or volume in the 3D case) and on the chosen criteria of acceptability. Commonly, parameters are calculated for the whole measured dose distribution. This may create problems in a number of ways. Film dosimetry is known to be less accurate at low dose, and planning systems are also less accurate in areas outside the treatment volume. Hence if the dose distribution contains large areas of low dose, the disagreements in these areas will dominate the calculated parameter. These differences may not be clinically significant and will therefore be misleading. On the other hand, if the low dose areas contain critical organs or regions of interest used in the IMRT optimization process, these dose differences can be clinically significant (Schwarz et al 2003) although they may still not be as important as dose agreement within the PTV. Our approach has been to confine the calculation to within the 80% isodose. This was a somewhat arbitrary choice but the investigations of Childress and Rosen (2003) using a similar approach suggested a value of 75% of the maximum computed dose as a surrogate for the PTV. This will yield a very similar area to our 80% of isocentre dose definition. However, the choice of area within which to calculate will affect the magnitude of the numerical parameter. A single hotspot will give a larger parameter value within a small PTV than with a large PTV. Therefore experience gained for one treatment site is not necessarily transferable to another site. And if there is a large variation in PTV size for a particular treatment site, the method is not strictly valid.
This problem has been addressed by Childress and Rosen (2003) who discuss the advantages and shortcomings of different dose comparison methods at length. Their approach aimed to produce a single value parameter which was biologically significant, physically meaningful and independent of image size and dose range. They introduced the concept of the normalized agreement test (NAT) index which combines dose and DTA errors within a given percentage dose representing the PTV, normalized to average dose. However, even this parameter proved dependent upon the proportion of the dose plane used in the calculation. They therefore concluded that the NAT index should be used to complement existing dose comparison methods.
Even if an ideal numerical parameter cannot be found, the data presented in this paper show that if a consistent methodology is used for a single treatment site with limited variation in PTV size from patient to patient then a single numerical parameter is a useful tool. Appropriate tolerances can be set to flag results requiring further investigation. Centres should adopt such parameters and begin to build up clinical experience which will enable them to interpret the significance of variation in the parameter for different treatment sites.
Measurement plane
A further question is that of which plane or planes should be used for verification measurements. The ideal would be to compare the combined 3D dose distribution from all fields. However, as yet, 3D tools such as gel dosimetry are expensive, time-consuming and not sufficiently accurate for routine use (MacDougall et al 2002) . A common alternative is to make measurements of the combined dose distribution in one or more selected twodimensional planes. The results shown in this paper clearly demonstrate the problems with this approach: the results will vary considerably depending upon both the plane orientation and position. Moreover, this approach inherently sub-samples the 3D dose space, meaning parts of the dose volume have not been verified (although if multiple planes are used this problem is less significant). If sagittal or coronal planes are chosen, the result will also be weighted towards beams orthogonal to the measurement plane; beams parallel to the measurement plane will only contribute to the plane from a single very narrow slit through the beam. If transverse planes are used, they are prone to the set-up errors and sub-sampling problems discussed in section 3.3.
The main alternative is to measure and compare each individual fluence map. This has the advantages that no part of any beam is omitted from the verification process and that fast automatic digital methods for fluence map acquisition and dose comparison are feasible using EPIDS (Van Esch et al 2001 , Warkentin et al 2003 or 2D arrays Nelms 2003, Létourneau et al 2004) . The disadvantages are that it results in more dose comparisons being required compared with a single film and that it exaggerates the significance of the errors detected in that they are likely to be smaller within the combined dose distribution. A promising approach to addressing this disadvantage is that of Renner et al (2003) who presented a method of calculating the combined dose distributions from measured fluence maps based on the original patient CT data thus allowing a direct comparison with the planned dose distribution within the actual patient geometry rather than a phantom geometry. Similar approaches have been taken by Partridge et al (2002) and Kapatoes et al (2001) who describe reconstructing 3D dose distributions from exit dose measurements but using megavoltage CT data of the patient acquired at the time of treatment. This method is strictly an in vivo verification since dose differences may be due to changes in patient shape and size as well as delivery errors. However, it could equally well be used on a phantom pre-treatment as a delivery verification method alone. This type of approach is currently the nearest to a full 3D verification and could be automated to provide an extremely efficient and thorough verification method. Richardson et al (2003) have described an unusual alternative method utilizing a film placed within a spiral phantom. This method has the advantage of sampling a much greater volume of the 3D dose distribution than a single plane film but requires modification of the planning system to calculate the dose in the spiral plane. It still requires film as the dosimeter rather than more efficient electronic methods.
The question of dose planes also raises the question of the phantoms used for verification. Ideally, measurements should be made within the planned patient geometry. In practice, this is not feasible since it would entail constructing an individual phantom for every patient. The nearest practical methods are those previously described which reconstruct fluence maps measured at build-up depth onto actual patient data. If this is not possible then phantoms which at least approximate the size, shape and composition of the clinical site should be used. For instance, for head and neck IMRT the ability of the planning system to correctly calculate dose at shallow depths, oblique incidences and in the presence of inhomogeneities must be tested therefore the phantom used should provide all these features.
Reduction in verification
In the introduction, the debate as to whether patient-specific verification can ever be dispensed with (Dube 2003 , Ramsey 2003 , Niemierko 2004 ) was referred to. It was stated that reduction of verification should only be considered when sufficient numbers of patients for a particular clinical site have been comprehensively verified and the IMRT system shown to be accurate, reproducible and stable. In the light of the experience described in this paper, we propose the following model for responsible reduction in patient-specific verification. It is proposed that it should be followed for each new IMRT treatment site or for a major change in technique:
(1) For the first cohort of patients a very thorough verification must be carried out. This should include ion chamber measurements, dose verification in a number of planes sampling the whole 3D dose distribution (or using a 3D dose reconstruction technique) and measurement of fluence maps. These data should be examined to determine the frequency and extent of dose differences. The dose comparisons should be carried out using quantitative parameters. The number of the patients in the cohort should be judged from the complexity of the treatment. A minimum number of 10 is suggested; the number chosen will need to be extended if the results are not consistent. (2) For a further cohort a reduced program of measurements should be established. These should be chosen based on the initial results. A verification dose plane (or planes) should be chosen that has been observed to be sensitive to errors in the total dose distribution or which includes critical structures to which the delivered dose is extremely important; it may be that the fluence maps are considered the most relevant planes for this stage. Ion chamber measurements should be continued during this phase; if it is intended to use a monitor unit (mu) check program, the measured and calculated data should be compared during this period. The quantitative criteria of acceptability and tolerances determined from the first phase should be consistently applied during this phase. A minimum number of 30 patients are suggested for this phase. (3) If the quantitative results have been consistent and completely free of significant error during the preceding stages, then the patient-specific verification may be dispensed with for the particular treatment site. However, the following safeguards must be in place. First, an extremely thorough IMRT-specific QC program. Part of this program should include a 'standard IMRT plan' which is re-delivered at regular intervals and rigorously and quantitatively checked to ensure that no changes have occurred. Second, an occasional patient should still be verified thoroughly to ensure that no undetected change in planning or delivery has arisen. These checks will verify the continuing accuracy of MLC positioning, and the download and delivery process which are the most likely sources of error at this stage. An independent mu check is still a necessity, though this may now be software based provided the comparison with measured doses has proved acceptable.
If there have been unexpected or unexplained errors, or if there is no consistency between planning system and measurement in the first two phases, then the verification must not be dispensed with. If less major changes occur, such as a software upgrade (although note that some software changes may be significant enough to begin this process again) or the extension of IMRT to a very similar treatment and site to that currently being treated, then the verification program may be scaled down, e.g., checking two or three patients very thoroughly and then performing the reduced set of measurements for ten patients.
Conclusion
In conclusion, we make the following recommendations for patient-specific IMRT verification:
• Quantitative parameters based on dose and DTA should be adopted as measures of the agreement between planned and delivered dose distributions. However, single value parameters should not be used alone but in conjunction with displays that show the position of areas of disagreement. Pass/fail displays are more useful than continuously varying colour displays for this purpose.
• The concept of dose/DTA criteria of acceptability (e.g., 3%/3 mm) for dose agreements should be adopted. Tolerances should be chosen based on clinical experience but should act as action levels rather than pass/fail test of a plan. The value of the chosen quantitative parameter and therefore the chosen tolerances will be dependent on the treatment site, area of dose plane evaluated, the dose plane used and the specified criterion of acceptability; therefore all these parameters should be consistent from plan to plan.
• Choose measurement planes which are relevant to the treatment being given and not insensitive to dose errors.
• Reduction in patient-specific verification should be carried out using the model proposed in this paper, but with proper caution.
If IMRT is to be used to its full potential then the patient-specific verification must be reduced and eventually eliminated. Planning and delivery systems which cannot meet the required standards of accuracy, reproducibility and stability will not be accepted by the radiotherapy community.
